Sichuan Biokin Pharmaceutical (688506.SH): The first patient has been enrolled in the Phase III clinical trial evaluating the postoperative adjuvant therapy of HER2 ADC for HER2-positive breast cancer with residual invasive cancer after neoadjuvant treatment.

Sichuan Biokin Pharmaceutical (688506.SH) announced that the company's independently developed innovative biopharmaceutical BL-M07D1 (HER2 ADC) has completed the enrollment of the first subject in a Phase III clinical trial comparing it to the injection drug trastuzumab emtansine (T-DM1) for adjuvant treatment after neoadjuvant therapy in HER2-positive breast cancer with residual invasive carcinoma. The announcement indicates that BL-M07D1 is a novel ADC targeting HER2 with best-in-class potential, and has shown significant anti-tumor efficacy in clinical trials.